CDTX (Cidara Therapeutics) Change In Receivables : $14.28 Mil (TTM As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Cidara Therapeutics Change In Receivables?

Cidara Therapeutics's change in receivables for the quarter that ended in Dec. 2024 was $0.01 Mil. It means Cidara Therapeutics's Accounts Receivable declined by $0.01 Mil from Sep. 2024 to Dec. 2024 .

Cidara Therapeutics's change in receivables for the fiscal year that ended in Dec. 2024 was $14.28 Mil. It means Cidara Therapeutics's Accounts Receivable declined by $14.28 Mil from Dec. 2023 to Dec. 2024 .

Cidara Therapeutics's Accounts Receivable for the quarter that ended in Dec. 2024 was $1.69 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Cidara Therapeutics's liquidation value for the three months ended in Dec. 2024 was $139.61 Mil.

Cidara Therapeutics Change In Receivables Historical Data

The historical data trend for Cidara Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cidara Therapeutics Change In Receivables Chart

Cidara Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-11.17

5.82

-0.48

-10.41

14.28

Cidara Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-13.07	8.97	4.66	0.65	0.01

Cidara Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.28 Mil.

Cidara Therapeutics (NAS:CDTX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Cidara Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1.694	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Cidara Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Cidara Therapeutics's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	189.825	-	51.488	+	0.75 * 1.694	+	0.5 * 0
=	139.61

Cidara Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Cidara Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Cidara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cidara Therapeutics Inc (NAS:CDTX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

20D0:Germany 20D0:Germany

Address

6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121

Website

https://www.cidara.com

Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Executives

Leslie Tari	officer: Chief Scientific Officer	C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR SUITE 101, SAN DIEGO CA 92121
Shane Ward	officer: CHIEF LEGAL OFFICER	C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Taylor Sandison	officer: Chief Medical Officer	6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Jeffrey Stein	director, officer: President & CEO	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Preetam Shah	officer: CFO & CBO	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Paul Daruwala	officer: Chief Medical Officer	6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Brady Johnson	officer: Dir. of Finance & Controller	6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Timothy R Franson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Carin Canale-theakston	director	C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR STE 101 CA 92121
Bonnie L Bassler	director	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
James E. Levine	officer: Chief Financial Officer	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Theodore R Schroeder	director	12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Chrysa Mineo	director	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
David L Gollaher	director	6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Daniel D Burgess	director	C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121